Abstract
Since the half-life of most angiogenic growth factors is several hours or less, sustained-release delivery would be optimal for their future clinical use. Two fibroblast growth factors, basic fibroblast growth factor (bFGF) and endothelial cell growth factor (ECGF), were delivered in two sustained- released modalities (poloxamer 407 and a gelatin sponge [Gelfoam]) to attempt to increase soft tissue vascularity. In vitro bioactivity of ECGF-poloxamer formulations was also tested on endothelial cell cultures. Among vascular- compromised skin flaps in rabbits, ECGF-poloxamer (N = 26), bFGF-poloxamer (N = 5), ECGF-poloxamer (N = 9, irradiated), and bFGF-Gelfoam flaps (N = 22) did not demonstrate significant differences in viability and vascularity compared to controls (p > .05). Irradiation had a detrimental effect on both flap vascularity and viability (p = .02). Future efforts for sustained delivery of angiogenic proteins are critical in order to make them clinically useful in wound healing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 109-116 |
| Number of pages | 8 |
| Journal | Annals of Otology, Rhinology and Laryngology |
| Volume | 105 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1996 |
Bibliographical note
Copyright:Copyright 2017 Elsevier B.V., All rights reserved.
Keywords
- growth factors
- neovascularization
- surgical flaps
- wound healing